Ubs Group Ag Evoke Pharma Inc Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.59 - $1.07 $1,066 - $1,933	-1,807 Reduced 62.01%	1,107 $0
Q4 2023 Feb 09, 2024	BUY	$1.05 - $1.39 $217 - $287	207 Added 7.65%	2,914 $3,000
Q3 2023 Nov 09, 2023	BUY	$0.96 - $1.73 $1,536 - $2,768	1,600 Added 144.53%	2,707 $3,000
Q3 2022 Nov 10, 2022	SELL	$1.95 - $3.43 $8,999 - $15,829	-4,615 Reduced 80.65%	1,107 $2,000
Q2 2022 Aug 10, 2022	BUY	$2.04 - $10.32 $11,672 - $59,051	5,722 New	5,722 $19,000

1.46K

Ticker EVOK
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 3,343,070
Market Cap $1.57M
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabeti...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.